2283-82-1

Basic information

• Product Name: Dehydroandrosterone
• Synonyms: 5-Androsten-3a-ol-17-one;(3R,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one;Androst-5-en-3α-ol-17-one;Isoandrostenolone;Δ5-Androstene-3α-ol-17-one;(3a)-3-hydroxy-Androst-5-en-17-one;3-alpha-Hydroxyandrost-5-ene-17-one;Dehydroandrosterone
• CAS NO: 2283-82-1
• Molecular Formula: C₁₉H₂₈O₂
• Molecular Weight: 288.42
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
• Mol File: 2283-82-1.mol
• Article Data: 9

Chemical Properties

• Melting Point: 148 °C
• Boiling Point: 426.7 °C at 760 mmHg
• Flash Point: 182.1 °C
• Appearance: /
• Density: 1.12 g/cm³
• Vapor Pressure: 4.54E-09mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethanol (Slightly, Heated), Methanol (Slightly, Heated)
• PKA: 15.02±0.60(Predicted)
• CAS DataBase Reference: Dehydroandrosterone(CAS DataBase Reference)
• NIST Chemistry Reference: Dehydroandrosterone(2283-82-1)
• EPA Substance Registry System: Dehydroandrosterone(2283-82-1)

Safety Data

• Hazardous Substances Data: 2283-82-1(Hazardous Substances Data)

Usage

Uses

Dehydro Androsterone is an Androsterone (A637535) analogue.

InChI:InChI=1/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14+,15+,16+,18+,19+/m1/s1

Synthetic route

(3R,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate (5223-99-4) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
With methanol; sodium hydroxide at 40℃; for 4h; Inert atmosphere;	95.8%
With potassium hydroxide In methanol for 1h; Heating;	1.9 g

17,17-ethylenedioxy-androst-5-ene-3α-ol (14456-21-4) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
With hydrogenchloride	80%
With hydrogenchloride In ethanol; water for 5h; Reflux;

dehydroepiandrosterone p-nitrobenzoate (1383292-25-8) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
With potassium hydroxide In methanol; water for 1h; Sonication;	72%
With NaOH In tetrahydrofuran; methanol; water

5-androstenedione (571-36-8) → dehydroepiandrosterone (53-43-0) + 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
With ethanol; nickel Hydrogenation;

3β-tosyloxyandrost-5-ene-17-one (2719-96-2) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
Multi-step reaction with 2 steps 1: 3.2 g / various solvent(s) / 4 h / 160 °C 2: 1.9 g / aq. KOH / methanol / 1 h / Heating View Scheme
Multi-step reaction with 2 steps 1: 3.2 g / tetra-n-butylammonium acetate / various solvent(s) / 4 h / 160 °C 2: 1.9 g / aq. KOH / methanol / 1 h / Heating View Scheme

3β-acetoxy-5α,6α-epoxy-androst-17-one, ethylene ketal (115350-45-3) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
Multi-step reaction with 5 steps 1: lithium aluminium tetrahydride 2: pyridine 3: N,N-dimethyl-aniline 4: potassium hydroxide 5: hydrogenchloride View Scheme
Multi-step reaction with 5 steps 1: lithium aluminium tetrahydride / tetrahydrofuran / 3 h / 35 °C / Reflux 2: pyridine / dichloromethane / 16 h / 10 - 20 °C / Cooling with ice 3: N,N-dimethyl-aniline / chloroform / 5 h / Reflux 4: potassium hydroxide; water / methanol / 1 h / Reflux 5: hydrogenchloride / ethanol; water / 5 h / Reflux View Scheme

17,17-ethylenedioxy-androstane-3β,5α-diol → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
Multi-step reaction with 4 steps 1: pyridine 2: N,N-dimethyl-aniline 3: potassium hydroxide 4: hydrogenchloride View Scheme
Multi-step reaction with 4 steps 1: pyridine / dichloromethane / 16 h / 10 - 20 °C / Cooling with ice 2: N,N-dimethyl-aniline / chloroform / 5 h / Reflux 3: potassium hydroxide; water / methanol / 1 h / Reflux 4: hydrogenchloride / ethanol; water / 5 h / Reflux View Scheme

17,17-ethylenedioxy-3β-methanesulfonyloxy-androstane-5α-ol (15577-68-1) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
Multi-step reaction with 3 steps 1: N,N-dimethyl-aniline 2: potassium hydroxide 3: hydrogenchloride View Scheme
Multi-step reaction with 3 steps 1: N,N-dimethyl-aniline / chloroform / 5 h / Reflux 2: potassium hydroxide; water / methanol / 1 h / Reflux 3: hydrogenchloride / ethanol; water / 5 h / Reflux View Scheme

5-androsten-3α-ol-17-one acetate 17-ethylene ketal (14456-20-3) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
Multi-step reaction with 2 steps 1: potassium hydroxide 2: hydrogenchloride View Scheme
Multi-step reaction with 2 steps 1: potassium hydroxide; water / methanol / 1 h / Reflux 2: hydrogenchloride / ethanol; water / 5 h / Reflux View Scheme

prasterone acetate → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
Multi-step reaction with 7 steps 1: p-toluenesulfonic acid monohydrate 2: 3-chloro-benzenecarboperoxoic acid 3: lithium aluminium tetrahydride 4: pyridine 5: N,N-dimethyl-aniline 6: potassium hydroxide 7: hydrogenchloride View Scheme
Multi-step reaction with 7 steps 1: orthoformic acid triethyl ester / toluene-4-sulfonic acid / 3 h / Inert atmosphere; Reflux 2: 3-chloro-benzenecarboperoxoic acid / dichloromethane / -5 - 20 °C 3: lithium aluminium tetrahydride / tetrahydrofuran / 3 h / 35 °C / Reflux 4: pyridine / dichloromethane / 16 h / 10 - 20 °C / Cooling with ice 5: N,N-dimethyl-aniline / chloroform / 5 h / Reflux 6: potassium hydroxide; water / methanol / 1 h / Reflux 7: hydrogenchloride / ethanol; water / 5 h / Reflux View Scheme

→ 3α-hydroxy-androst-5-en-17-one

Conditions	Yield
Multi-step reaction with 6 steps 1: 3-chloro-benzenecarboperoxoic acid 2: lithium aluminium tetrahydride 3: pyridine 4: N,N-dimethyl-aniline 5: potassium hydroxide 6: hydrogenchloride View Scheme
Multi-step reaction with 6 steps 1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / -5 - 20 °C 2: lithium aluminium tetrahydride / tetrahydrofuran / 3 h / 35 °C / Reflux 3: pyridine / dichloromethane / 16 h / 10 - 20 °C / Cooling with ice 4: N,N-dimethyl-aniline / chloroform / 5 h / Reflux 5: potassium hydroxide; water / methanol / 1 h / Reflux 6: hydrogenchloride / ethanol; water / 5 h / Reflux View Scheme

Androstenedione (63-05-8) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
Multi-step reaction with 4 steps 1.1: potassium tert-butylate / tert-butyl alcohol / 1 h / 30 - 35 °C / Inert atmosphere 1.3: 65 h / 45 °C / pH 6.5 / Enzymatic reaction 2.1: D-glucose; NAD; glucose dehydrogenase (CDX-901)_; ketoreductase from Sphingomonas wittichii; potassium carbonate / ethyl acetate; aq. phosphate buffer / 21 h / 32.5 °C / pH 6.3 - 6.5 / Inert atmosphere; Enzymatic reaction 3.1: triphenylphosphine; di-isopropyl azodicarboxylate / tetrahydrofuran / 5 - 20 °C / Inert atmosphere 4.1: potassium hydroxide / water; methanol / 1 h / Sonication View Scheme
Multi-step reaction with 4 steps 1: potassium tert-butylate / tert-butyl alcohol / 1 h / 30 - 35 °C / Inert atmosphere 2: D-glucose; NAD; glucose dehydrogenase (CDX-901)_; ketoreductase from Sphingomonas wittichii; potassium carbonate / ethyl acetate; aq. phosphate buffer / 21 h / 32.5 °C / pH 6.3 - 6.5 / Inert atmosphere; Enzymatic reaction 3: triphenylphosphine; di-isopropyl azodicarboxylate / tetrahydrofuran / 5 - 20 °C / Inert atmosphere 4: potassium hydroxide / water; methanol / 1 h / Sonication View Scheme

dehydroepiandrosterone (53-43-0) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions	Yield
Multi-step reaction with 2 steps 1: triphenylphosphine; di-isopropyl azodicarboxylate / tetrahydrofuran / 5 - 20 °C / Inert atmosphere 2: potassium hydroxide / water; methanol / 1 h / Sonication View Scheme

5-androstenedione (571-36-8) → 3α-hydroxy-androst-5-en-17-one (2283-82-1)

Conditions

Yield

Multi-step reaction with 3 steps 1: D-glucose; NAD; glucose dehydrogenase (CDX-901)_; ketoreductase from Sphingomonas wittichii; potassium carbonate / ethyl acetate; aq. phosphate buffer / 21 h / 32.5 °C / pH 6.3 - 6.5 / Inert atmosphere; Enzymatic reaction 2: triphenylphosphine; di-isopropyl azodicarboxylate / tetrahydrofuran / 5 - 20 °C / Inert atmosphere 3: potassium hydroxide / water; methanol / 1 h / Sonication View Scheme

Upstream product

• 571-36-8 5-androstenedione 
• 1383292-25-8 dehydroepiandrosterone p-nitrobenzoate 
• 53-43-0 dehydroepiandrosterone 
• 63-05-8 Androstenedione 
• 14456-20-3 3β-acetoxy-5-androsten-17-one-17-ethyleneketal 
• 853-23-6 prasterone acetate 
• 14456-21-4 17,17-ethylenedioxy-androst-5-ene-3α-ol 
• 14456-20-3 5-androsten-3α-ol-17-one acetate 17-ethylene ketal 
• 15577-68-1 17,17-ethylenedioxy-3β-methanesulfonyloxy-androstane-5α-ol 
• 13262-99-2 17,17-ethylenedioxy-androstane-3β,5α-diol 
• 115350-45-3 3β-acetoxy-5α,6α-epoxy-androst-17-one, ethylene ketal 
• 2719-96-2 3β-tosyloxyandrost-5-ene-17-one 
• 5223-99-4 (3R,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate 
• 1093-91-0 (3S,8R,9S,10R,13S,16R)-16-Bromo-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one 

Downstream Products

• 5419-51-2 3β-(2-tetrahydropyranyloxy)-5-androstene-17β-0l 
• 566-19-8 3β-hydroxyandrost-5-ene-7,17-dione 
• 14167-51-2 5-androstene-3α,16α-diol-17-one 
• 853-23-6 3β-acetoxy-5-androsten-17-one 
• 53-43-0 dehydroepiandrosterone 
• 853-23-6 prasterone acetate 
• 63-05-8 Androstenedione 
• 63015-10-1 3β-Hydroxy-17-hydrazono-androsten-(5) 
• 628-13-7 pyridine hydrochloride 
• 133522-45-9 14β-androst-5-ene-3β,17α-diyl 3-acetate 17-p-toluenesulfonate 
• 1016226-71-3 16α-bromo-5-androst-5-ene-17-one-3α-ol 
• 16895-59-3 androst-5-ene-3α,17β-diol 
• 63-05-8 (8R,9S,10R,13S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17(2H,6H)-dione 
• 571-36-8 3,17-Dioxo-androsten-5 

Relevant articles and documents

Steroid compound 3-site hydroxyl configuration inversion method

The invention discloses a steroid compound 3-site hydroxyl configuration inversion method. The method specifically comprises the following steps that (1) a steroid compound containing a 3-site hydroxyl reacts with an acyl chloride compound; (2) the product obtained in the step (1) and a substituting agent are subjected to SN2 nucleophilic substitution reaction under existing of a phase transfer catalyst; and (3) the product obtained in the step (2) is subjected to a hydrolysis reaction. Compared with a Mitsunobu method, the method does not need to use triphenylphosphine and azodiformate pricedhigher, and accordingly the production cost is greatly lowered; meanwhile, a p-nitrobenzoic acid derivative which seriously affects the water environment does not need to be used, and therefore the method is more environmentally friendly. The method adopts cesium acetate/18-crown ether-6 system to conduct 3-site hydroxyl configuration inversion, can remarkably reduce occurrence of side reactions,accordingly a higher reaction yield is obtained, and the method is finally applicable to industrialized production.

Development of a Chemoenzymatic Process for Dehydroepiandrosterone Acetate Synthesis

Dehydroepiandrosterone (DHEA, 2) is an important endogenous steroid hormone in mammals used in the treatment of a variety of dysfunctions in female and male health,1 as well as an intermediate in the synthesis of steroidal drugs, such as abiraterone acetate which is used for the treatment of prostate cancer.2-4 In this manuscript we describe a novel, concise, and cost-efficient route toward DHEA (2) and DHEA acetate (3) from 4-androstene-3,17-dione (4-AD, 1). Crucial to success was the identification of a ketoreductase from Sphingomonas wittichii for the highly regio- and stereoselective reduction of the C3-carbonyl group of 5-androstene-3,17-dione (5) to the required 3β-alcohol (2, >99% de). The enzyme displayed excellent robustness and solvent stability under high substrate concentrations (up to 150 g/L).

STEROID TETROL SOLID STATE FORMS-2

The invention relates to solid state forms of androst-5-ene-3α,7β,16α,17β- tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes.